Company watchers remained upbeat as analysts during a conference call Friday pressed Immunomedics Inc. for details about the complete response letter (CRL) regarding the BLA related to antibody-drug conjugate (ADC) sacituzumab govitecan for metastatic triple-negative breast cancer (TNBC).